tianjin dev (00882) announced on September 26, 2024, that its indirectly non-wholly owned subsidiary tianjin lisheng pharmaceutical has entered into a third cbhb wealth management agreement with cbhb, subscribing to another structured deposit with a principal amount of RMB 0.21 billion (equivalent to approximately HKD 0.231 billion).
天津发展附属力生制药认购本金金额2.1亿元结构性存款
tianjin dev affiliated tianjin lisheng pharmaceutical subscribed principal amount of 0.21 billion yuan for structured deposits.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated